- Home
- HHS vs RLYB Comparison
HHS vs RLYB Comparison
Compare HHS & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HHS | RLYB |
|---|---|---|
| Founded | 1923 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.2M | 28.7M |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HHS | RLYB |
|---|---|---|
| Price | $2.37 | $8.53 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.0K | ★ 253.9K |
| Earning Date | 03-17-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 97.35 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $159,570,000.00 | $858,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 43.00 |
| 52 Week Low | $2.31 | $0.22 |
| 52 Week High | $5.39 | $11.49 |
Technical Indicators
Market Signals| Indicator | HHS | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 30.21 | 56.75 |
| Support Level | $2.33 | $0.48 |
| Resistance Level | $3.03 | $11.49 |
| Average True Range (ATR) | 0.07 | 0.67 |
| MACD | -0.03 | -0.42 |
| Stochastic Oscillator | 10.00 | 8.82 |
Price Performance
Historical ComparisonAbout HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.